Proteolysis of CD44 at the cell surface controls a downstream protease network.
ADAM10
CD44
MMP14
MMP2
cell adhesion
meprin β
shedding
tumor spheroid
Journal
Frontiers in molecular biosciences
ISSN: 2296-889X
Titre abrégé: Front Mol Biosci
Pays: Switzerland
ID NLM: 101653173
Informations de publication
Date de publication:
2023
2023
Historique:
received:
24
08
2022
accepted:
31
01
2023
entrez:
6
3
2023
pubmed:
7
3
2023
medline:
7
3
2023
Statut:
epublish
Résumé
The cell surface receptor cluster of differentiation 44 (CD44) is the main hyaluronan receptor of the human body. At the cell surface, it can be proteolytically processed by different proteases and was shown to interact with different matrix metalloproteinases. Upon proteolytic processing of CD44 and generation of a C-terminal fragment (CTF), an intracellular domain (ICD) is released after intramembranous cleavage by the γ-secretase complex. This intracellular domain then translocates to the nucleus and induces transcriptional activation of target genes. In the past CD44 was identified as a risk gene for different tumor entities and a switch in CD44 isoform expression towards isoform CD44s associates with epithelial to mesenchymal transition (EMT) and cancer cell invasion. Here, we introduce meprin β as a new sheddase of CD44 and use a CRISPR/Cas9 approach to deplete CD44 and its sheddases ADAM10 and MMP14 in HeLa cells. We here identify a regulatory loop at the transcriptional level between ADAM10, CD44, MMP14 and MMP2. We show that this interplay is not only present in our cell model, but also across different human tissues as deduced from GTEx (Gene Tissue Expression) data. Furthermore, we identify a close relation between CD44 and MMP14 that is also reflected in functional assays for cell proliferation, spheroid formation, migration and adhesion.
Identifiants
pubmed: 36876041
doi: 10.3389/fmolb.2023.1026810
pii: 1026810
pmc: PMC9981664
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1026810Informations de copyright
Copyright © 2023 Wöhner, Li, Hey, Drobny, Werny, Becker-Pauly, Lucius, Zunke, Linder and Arnold.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Cell Physiol Biochem. 2018;46(3):1218-1230
pubmed: 29672299
J Cell Sci. 2019 May 31;132(11):
pubmed: 31076514
Cells. 2020 May 24;9(5):
pubmed: 32456348
Cancer Res. 1994 Jan 15;54(2):422-6
pubmed: 7506122
Nat Commun. 2012 Jun 06;3:883
pubmed: 22673910
J Hematol Oncol. 2018 May 10;11(1):64
pubmed: 29747682
FASEB J. 2020 May;34(5):6675-6687
pubmed: 32237095
Biochim Biophys Acta Mol Cell Res. 2022 Jan;1869(1):119136
pubmed: 34626678
Sci Rep. 2017 Mar 09;7:44053
pubmed: 28276471
Cancer Res. 2002 Jul 15;62(14):3962-5
pubmed: 12124327
Crit Rev Clin Lab Sci. 2002 Nov;39(6):527-79
pubmed: 12484499
Front Mol Biosci. 2021 Oct 06;8:702341
pubmed: 34692768
EMBO J. 2002 Aug 1;21(15):3949-59
pubmed: 12145196
Cell Signal. 2003 Sep;15(9):829-41
pubmed: 12834808
Biochim Biophys Acta Mol Cell Res. 2017 Nov;1864(11 Pt B):2096-2104
pubmed: 28502593
Int J Cancer. 1999 Jan 29;80(3):387-95
pubmed: 9935179
Oncogene. 2003 Nov 27;22(54):8716-22
pubmed: 14647466
J Neurooncol. 2019 Nov;145(2):201-210
pubmed: 31506754
Oncology. 1999 Apr;56(3):232-8
pubmed: 10202279
J Cell Biol. 2001 Nov 26;155(5):755-62
pubmed: 11714729
Mol Biol Cell. 1996 Mar;7(3):383-96
pubmed: 8868467
J Cell Biol. 1991 Apr;113(1):207-21
pubmed: 2007624
Oncotarget. 2015 Apr 10;6(10):7828-37
pubmed: 25797261
Nucleic Acids Res. 2019 Jul 2;47(W1):W556-W560
pubmed: 31114875
J Biol Chem. 1993 Jun 15;268(17):12235-8
pubmed: 8509359
J Invest Dermatol. 2009 Jun;129(6):1321-4
pubmed: 19434087
RNA Biol. 2009 Nov-Dec;6(5):546-62
pubmed: 19829082
Cancer Res. 1995 May 1;55(9):1831-5
pubmed: 7537174
Cancer Invest. 1999;17(8):581-5
pubmed: 10592765
Clin Dev Immunol. 2012;2012:708036
pubmed: 22693526
Front Oncol. 2019 Apr 30;9:309
pubmed: 31114754
Nat Rev Cancer. 2011 Apr;11(4):254-67
pubmed: 21390059
J Cell Biol. 2004 Jun 21;165(6):893-902
pubmed: 15197174
Stem Cells Int. 2016;2016:2087204
pubmed: 27200096
J Clin Invest. 2011 Mar;121(3):1064-74
pubmed: 21393860
FASEB J. 2019 Jun;33(6):7490-7504
pubmed: 30916990
Science. 1996 Jan 26;271(5248):509-12
pubmed: 8560266
Sci Rep. 2016 May 06;6:25550
pubmed: 27151651
Cell Physiol Biochem. 2018;51(4):1879-1893
pubmed: 30504723
Cell. 1990 Jun 29;61(7):1303-13
pubmed: 1694723
Mol Cancer Res. 2015 Jan;13(1):9-15
pubmed: 25566991
J Invest Dermatol. 2009 Jun;129(6):1471-82
pubmed: 18971959
Cancer Sci. 2004 Dec;95(12):930-5
pubmed: 15596040
Genes Dev. 2002 Dec 1;16(23):3074-86
pubmed: 12464636
Nucleic Acids Res. 2019 Jan 8;47(D1):D442-D450
pubmed: 30395289
J Biol Chem. 2012 Jun 1;287(23):18995-9007
pubmed: 22433859
Oncogene. 2003 Mar 13;22(10):1511-6
pubmed: 12629514
Cell. 1989 Mar 24;56(6):1063-72
pubmed: 2466576
J Cell Biol. 1996 Mar;132(6):1199-208
pubmed: 8601595
Nat Rev Mol Cell Biol. 2003 Jan;4(1):33-45
pubmed: 12511867
Mol Brain. 2008 Nov 04;1:15
pubmed: 18983676
J Cell Physiol. 1998 Jul;176(1):206-15
pubmed: 9618160
Int Immunol. 2008 Sep;20(9):1181-7
pubmed: 18635581
Genes Dev. 2002 Feb 1;16(3):307-23
pubmed: 11825873
Front Cell Dev Biol. 2021 Mar 02;9:622390
pubmed: 33738281
Proc Natl Acad Sci U S A. 1992 Dec 15;89(24):12160-4
pubmed: 1465456
Cell. 1997 Jul 25;90(2):271-80
pubmed: 9244301
J Biol Chem. 2012 Oct 19;287(43):36435-42
pubmed: 22961986
Anticancer Res. 2006 Jul-Aug;26(4B):2863-72
pubmed: 16886606
Int J Mol Sci. 2020 Dec 20;21(24):
pubmed: 33419373
Oncotarget. 2017 Jul 4;8(33):54873-54888
pubmed: 28903388
Cancer Sci. 2017 Mar;108(3):347-353
pubmed: 27987367
J Cell Biol. 2001 May 28;153(5):893-904
pubmed: 11381077
Front Cell Dev Biol. 2018 Nov 06;6:153
pubmed: 30460232
J Cell Biol. 1995 Feb;128(4):687-98
pubmed: 7532176
Mol Neurodegener. 2018 Apr 6;13(1):18
pubmed: 29625583
Behav Brain Res. 2022 Sep 5;433:113977
pubmed: 35752274
Cancer Res. 2004 Feb 1;64(3):876-82
pubmed: 14871815
Cancer Res. 1997 Mar 1;57(5):846-9
pubmed: 9041184
Cell Physiol Biochem. 2017;43(6):2489-2504
pubmed: 29131012
FASEB J. 2017 Mar;31(3):1226-1237
pubmed: 28003343
Breast Cancer Res. 2012 May 23;14(3):R84
pubmed: 22621373